This study evaluates the effect of intramuscular injected methylprednisolone treating birch pollen induced rhinitis compared to placebo.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Severe birch pollen induced allergic rhinitis.
* Signed informed consent according to International Council of Harmonisation/Good Clinical Practice, and national/local regulations.
* Women of considered childbearing potential (WOCBP) will only be included after a negative highly sensitive pregnancy test according to CTFG recommendations.
Exclusion Criteria:
* Pregnancy or nursing.
* Autoimmune or collagen disease.
* Cardiovascular disease.
* Hepatic disease.
* Renal disease.
* Cancer.
* Upper airway disease (non-allergic sinusitis, nasal polyposis, chronic obstructive- and restrictive lung disease).
* Medication with a possible side-effect of interfering with the immune response.
* Previous immuno- or chemotherapy.
* Chronic disease.
* Major metabolic disease.
* Alcohol or drug abuse.
* Mental incapability of coping with the study.
* Known or suspected allergy to the study product.
* Suspicion of or confirmed bacterial infection.
* Known allergy to the study drugs, "rescue medication".